Obsessive compulsive disorder (OCD) is a common illness, characterized by anxietyprovoking thoughts and the need to perform rituals. OCD is most commonly treated with a class of pharmacological agents known as serotonin reuptake inhibitors (SRIs). SRIs block the reuptake of serotonin (5-HT) into the presynaptic neuron, a process mediated by the serotonin transporter (5-HTT). The successful use of SRIs in OCD has led to the hypothesis that 5-HTT may play a pivotal role in the pathogenesis of OCD. We decided to study this hypothesis from a genetic perspective, because family and twin studies suggest that there is a strong genetic component to OCD. In addition, the sequence of the gene for 5-HTT is available, and a 44-bp insertion/deletion polymorphism has been detected in the promoter region of the gene. There is evidence that this polymorphism alters expression of the transporter protein. We typed 72 OCD patients and 72 matched controls, and found no statistically significant difference between the two groups ( 2 = 4.319, P = 0.115, 2 d.f.). We observed however a trend towards increased homozygosity in the patient group. We also rated (retrospectively) the patients' clinical responses to SRIs. No association was observed between these ratings and the promoter region polymorphism in the serotonin transporter gene. Given the pharmacological evidence favoring a role for 5-HTT in OCD and SRI response, further genetic evaluation of the serotonin transporter in OCD is indicated.
Introduction
prompting the first research into the biological properties of the serotonin transporter. The sequence of the Obsessive compulsive disorder (OCD) is a relatively human serotonin transporter (5-HTT) cDNA has been common condition, characterized by persistent, determined 2,3 and the gene localized to chromosome unwanted thoughts and ritualistic behaviors. The 17. 3, 4 Altemus et al 5 sequenced the coding region of the involvement of a genetic factor in OCD is likely, based 5-HTT gene in 22 OCD patients, but found no evidence on the results of family and twin studies. 1 Although of amino acid substitution or nucleotide change in the pattern of inheritance in OCD does not appear to either the cases or the four controls. Further sequenbe straightforward, molecular studies may provide cing by Heils et al 6 upstream from the gene's coding valuable clues as to the contribution of genetic factors region revealed a polymorphic site in the promoter in the disorder. We chose to study, at the DNA level, region. Our study of the 5-HTT gene in OCD was based the role of the serotonin transporter gene in OCD. Our on this polymorphism, a 44-bp insertion/deletion. This study was prompted by an accumulating body of polymorphism is of interest in OCD for two reasons. research pointing to the importance of the serotonin First, in vitro research has shown that the polymortransporter in this disorder.
phism has an effect on gene expression. The long allele The primary pharmacologic agents useful in treating of 5-HTT produces expression levels three times OCD, the serotonin reuptake inhibitors (SRIs) congreater than the short allele. 6, 7 This genetic variation sisting of clomipramine and the selective SRIs, block could be an important factor in determining risk for serotonin reuptake, a process mediated through the OCD, a disorder in which dysregulation of the serotransporter. This observation was responsible for tonergic system has been suggested by biological and pharmacological research. 8 Second, the polymorphism has been associated with the personality traits Neuro- in an OCD population.
The purpose of the present study was to test for an using a simple three-point system. A rating of 3 was association between OCD and the serotonin transporter assigned if there was clear documentation that their gene. We also hypothesized that variation at the 5-HT symptoms had improved, ie if target symptoms were transporter gene may be important in determining the estimated to decrease in severity by at least 25%. A clinical response of OCD patients to serotonin reuptake reduction in symptom severity of 25% is generally inhibitors (SRIs). Clinically, there is significant variaaccepted as clinically significant in prospective drug bility in response to SRIs among the OCD population, trials. Examples of monitored target symptoms that in that 40-60% remain unimproved after a sufficient determined response score included total number of trial. 11 Studies have shown that chronic treatment with handwashes daily, time required to check prior to SRIs causes changes in the expression of the 5-HTT departing from home, or total time spent daily on ritugene. 12 It may be that the effectiveness of SRIs is depenals or obsessive ruminations. Patients with no change dent upon a particular individual's pre-treatment level over the 10-week trial were assigned a rating of 1. of 5-HTT expression, which appears to be controlled
Patients in which benefits were less than 25% were by the polymorphism in the promoter region. Another assigned a rating of 2. However, ratings were only possibility is that treatment response depends upon an assigned if the minimum dosage levels outlined above individual's genetic ability to adjust 5-HTT expression, had been achieved with good compliance, as evaluated in response to activation of signal transduction casby the treating psychiatrist. cades. It is widely believed that amelioration of OCD Control subjects were matched to the patients based symptoms with an SRI is the result of down-regulation on sex, ethnic background, and age. Ancestry was of 5-HT receptors. 8 The level of 5-HTT expression determined in both patients and controls based on could affect the amount of serotonin in the synaptic descriptions given by each individual. The descripcleft, therefore contributing to the down-regulation of tions included items such as primary language spoken, the post-synaptic serotonin receptors. To test these religious affiliation, maiden surnames, and birthplace. hypotheses, we conducted a preliminary, retrospective Age matches were within 5 years, and this was constudy where ratings were assigned to the OCD patients sidered adequate to eliminate cohort effects (for based on their clinical response to SRIs. We tested for example, due to waves of immigration). Some of the an association between these ratings and variation at controls were anonymous DNA samples obtained from the polymorphic site in the promoter of the serotonin DNA diagnostic laboratories in Toronto (n = 22). It was transporter gene.
not known if the donors of these DNA samples suffered from any psychiatric illnesses. Eight of the controls Materials and methods were staff and students at the Clarke Institute of Psychiatry. The majority of the controls (n = 42) were Subjects obtained using poster or newspaper advertisements The patients in this study were consecutive referrals to which invited the public to participate in genetic studthe Anxiety Disorders Clinic at the Clarke Institute of ies of psychiatric illness. All of the individuals who Psychiatry. All patients were diagnosed by experiresponded to these advertisements were interviewed enced psychiatrists following a 2-h clinical interview using the Structured Clinical Interview for DSM-IV which included Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings, and incorporated mood, anxi-(SCID), and only subjects who had no significant hisety, and psychotic disorder questions based on the tory of psychiatric illness in themselves or in their firstStructured Clinical Interview for DSM-IV (SCID) and degree relatives were included as controls. The identthe Schedule for Affective Disorders and Schizoities of all subjects were made anonymous by assignphrenia -Lifetime Anxiety version (SADS-LA). OCD ment of code numbers. The average age of the controls patients with a history of metabolic or neurological diswas 36.4 ± 8.6 years. The sample consisted of 38 ease were excluded from the study, as were those with women and 34 men. schizophrenia, schizoaffective disorder, other psychotic conditions, or significant history of substance dependence. The average age of the patients was Genetic typing 36.3 ± 8.4 years.
Genomic DNA was extracted from the whole blood.
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Patients were evaluated retrospectively with respect A PCR protocol was used to amplify a segment of gento their clinical response to SRIs. A checklist was comomic DNA containing the insertion/deletion polymorpleted on each patient, based on information from phism in the promoter region of the serotonin transchart reviews and discussions with the treating psyporter gene. 6 PCR products were subjected to chiatrist. The criteria used were as follows: the patient electrophoresis on 3.5% agarose gel and visualized must have had a clinically adequate trial. This was under ultraviolet light in the presence of ethidium brodefined as 10 weeks of treatment at a dosage of at least mide. DNA bands were assigned allele numbers based 60 mg of fluoxetine per day or 150 mg clomipramine on their size (allele 1 = 528 bp; allele 2 = 484 bp), per day, or the maximum dosage that was tolerated which was determined by comparing their migration (patients who took equivalent doses of fluvoxamine, in the gel with a 1-kb ladder (Gibco, Gaithersburg, paroxetine or sertraline were also included in the MD, USA). study). Patients were then rated on symptom severity, 
Statistical analysis Discussion
Chi-squared analyses were carried out on 2 × 2 and 2 × 3 tables. A continuity correction of . was applied Statistical analysis of our total sample (n = 72) failed to reveal an association between OCD and an to the 2 × 2 tables. To look for trends, an average medication response rating was calculated for patients of insertion/deletion polymorphism in the promoter of the serotonin transporter gene. We did observe a trend, each genotype (1-1, 1-2, and 2-2). A power analysis was performed for this study, specifying ␣ = 0.05 and P 0 however, in that the patients in our study tended to be homozygous more often than controls ( 2 = 3.372, (the proportion of the normal population with the risk allele) = 0.40. The study was determined to have 80% P = 0.066, 1 d.f.). This trend became statistically significant in a smaller sample, which consisted of the power to detect a difference between patients and controls when the proportion of the patients with the risk subset of controls who had had SCID diagnostic interviews (n = 42). In this sample, patients were more allele is 0.72.
likely to be homozygous than controls ( 2 = 9.381, P = 0.002, 1 d.f.), but this probably represents a spuriResults ous finding because of the small sample size. If one considers the possibility that the trend may indeed be The 5-HTT genotypes and allele frequencies are displayed in Table 1 . There was no statistically significant representative of an actual genetic difference in OCD patients, this points to the existence of genetic heterodifference between OCD patients and matched controls in their genotype counts ( 2 = 4.319, P = 0.155, 2 d.f.) geneity in OCD (because clearly not all the OCD patients were homozygous). or allele frequencies ( 2 = 0.014, P = 0.906, 1 d.f.). The OCD patients were divided into two groups based on
The trend for OCD patients to be homozygous more often than controls was interesting, given the previous their response (patients with ratings of 3) or lack of response (patients with ratings of 1) to SRIs, as shown finding by Heils et al 8 correlating allelic variation with expression of the transporter protein. The long allele in Table 1 . No significant 5-HTT genetic differences were observed between responders and non-(allele 1) produces levels of expression three times higher than the short allele. Since homozygotes have responders (allele frequencies: Neuroticism and Harm Avoidance. We hypothesized that these personality traits may be modifying factors 2 = 2.951, P = 0.229, 2 d.f.). Likewise, patients who were treated with fluoxetine did not differ significontributing to OCD; thus we expected to see an increased rate of the number 2 allele in OCD patients, cantly, based on their response to the drug, in 5-HTT allele or genotype frequencies (23 responders, 14 nonor an increase in the 2-2 homozygote. While there was no significant difference in allele counts, there was a responders; alleles: 2 = 0.015, P = 0.902, 1 d.f.; genotypes: 2 = 0.168, P = 0.919, 2 d.f.). None of the patient trend toward the 2-2 homozygote being increased in patients vs controls (24% and 14% respectively). or control groups deviated significantly from HardyWeinberg equilibrium.
Based on our analysis, the polymorphism in the sero-
